Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 28;5(2):e524.
doi: 10.1097/HS9.0000000000000524. eCollection 2021 Feb.

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Renaud Heine  1 , Frederick W Thielen  1 , Marc Koopmanschap  1 , Marie José Kersten  2 , Hermann Einsele  3 , Ulrich Jaeger  4 , Pieter Sonneveld  5 , Jorge Sierra  6 , Carin Smand  7 , Carin A Uyl-de Groot  1   8
Affiliations

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

Renaud Heine et al. Hemasphere. .

Abstract

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. We focused on the former France, Germany, Spain, Italy and the United Kingdom (EU-5) and the Netherlands. We conducted a review of list prices, health technology assessment reports, budget impact analysis dossiers, and published cost-effectiveness analyses. We forecasted the 10-year health expenditures on CAR T-cells for several hematological cancers in selected European Union countries. Nine cost-effectiveness studies were identified and list prices for CAR T-cell therapies ranged between 307 200 EUR and 350 000 EUR. Estimated additional costs for pre- and post-treatment were 50 359 EUR per patient, whereas the incremental costs of CAR T-cell therapy (when compared with care as usual) ranged between 276 086 EUR and 328 727 EUR. We estimated market entry of CAR T-cell therapies for chronic mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia in 2021, 2022, 2022, 2022, and 2025, respectively. Cumulative expenditure estimates for existing and future indications from 2019 to 2029 were on average 28.5 billion EUR, 32.8 billion EUR, and 28.9 billion EUR when considering CAR T-cell therapy costs only, CAR T-cell therapy costs including pre- and post-treatment, and incremental CAR T-cell therapy costs, respectively. CAR T-cell therapies seem to be promising treatment options for hematological cancers but the financial burden on healthcare systems in the former EU-5 and the Netherlands will contribute to a substantial rise in healthcare expenditure in the field of hematology.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Flowchart of forecast approaches. CAR-T = chimeric antigen receptor T cell.
Figure 2.
Figure 2.
Total average costs per country in scenario 1 (all indications).
Figure 3.
Figure 3.
Total average costs per country in scenario 2 (all indications).
Figure 4.
Figure 4.
Expenditure forecast per scenario (all countries and indications). CAR-T = chimeric antigen receptor T cell.
See this image and copyright information in PMC

References

    1. Jürgens B, Clarke NS. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol. 2019; 37:370–375. - PubMed
    1. Charrot S, Hallam S. CAR-T cells: future perspectives. HemaSphere. 2019; 3:e188. - PMC - PubMed
    1. Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020; 34:631–646. - PMC - PubMed
    1. Eurostat. People in the EU - Population Projections. 2017. Available at: https://ec.europa.eu/eurostat/databrowser/view/proj_19np/default/table?l.... Accessed January 20, 2021.
    1. European Commission. European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2018, for All Countries. 2018. Available at: https://ecis.jrc.ec.europa.eu. Accessed January 20, 2021.

LinkOut - more resources